Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis

뉴스 본문을 불러오고 있어요.

Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis | 웨이프 WAPE

Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis

기사 요약

관련 종목

댓글 —